MINK THERAPEUTICS INC

NASDAQ: INKT (MiNK Therapeutics, Inc.)

最近更新时间: 2天之前, 4:44PM

8.02

-0.59 (-6.85%)

前收盘价格 8.61
成交量 18,935
平均成交量 (3个月) 15,631
市值 41,171,836
价格/销量 (P/S) 218.69
52周波幅
7.76 (-3%) — 16.93 (111%)
利润日期 11 Nov 2026
营业利益率 (TTM) -5,720.70%
稀释每股收益 (EPS TTM) -2.23
流动比率 (MRQ) 0.970
营业现金流 (OCF TTM) -7.16 M
杠杆自由现金流 (LFCF TTM) -6.21 M
资产报酬率 (ROA TTM) -61.63%

AIStockmoo 评分

-2.9
盈利能力弱。短期流动性偏紧。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
资本回报 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年没有明确趋势。股价远低于52周高点。 参考
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
持仓情绪 参考 NA
机构在最新13F申报中净-0.08%的股份:7家增持,10家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-15.2%,回补天数4.3天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
每股盈利逐年上升。近年曾亏损。 参考
低于中期趋势线。 参考
股价低于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向下。短期动能下降。 参考
支撑与阻力没有明确信号。 参考
最终评分 -2.89
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 MiNK Therapeutics, Inc. 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B 评分
INKT 41 M - - - -2.9
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

部门 Healthcare
行业 Biotechnology
内部持股比例 59.34%
机构持股比例 3.79%

所有权

姓名 日期 持有股份
Longbow Finance Sa 30 Sep 2026 16,667
Paladin Partners, Llc 30 Sep 2026 500
Covestor Ltd 30 Sep 2026 119

该时间范围内无数据。

机构

机构持股比例: 5.11%

持仓变动 机构数 股数
增持 7 42,714
减持 10 31,208
新建仓 1 72
清仓 4 15,468

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 55,094 4.3
15 Oct 2026 47,778 2.4
30 Sep 2026 49,583 3.1
15 Sep 2026 57,136 3.1
31 Aug 2026 64,965 6.8
14 Aug 2026 78,320 9.0

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

6 正面 0 负面 1 中性
日期 类型 细节
11 Nov 2026 Yahoo Finance MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
First revenue lands as the ARDS trial enters randomized Phase II.
11 Nov 2026 Yahoo Finance MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q3 2026 earnings call…
11 Nov 2026 Yahoo Finance MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months.
11 Nov 2026 Yahoo Finance What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear…
11 Nov 2026 Yahoo Finance MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
MiNK Therapeutics, Inc. (INKT) delivered earnings and revenue surprises of +24.24% and +33.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
11 Nov 2026 Yahoo Finance MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living…
06 Nov 2026 Yahoo Finance MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale for an ongoing Phase 2 combination studySenolytic activity: agenT-797 and…
02 Nov 2026 Yahoo Finance MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingNEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE)…
02 Oct 2026 Yahoo Finance MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW…
30 Sep 2026 Yahoo Finance MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand…

技术形态 中期

趋势排列
斜率
入场位置
成交量
下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。
最近阻力: 8.30 – 8.66 · 中等

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票